摘要
为了观察抗肿瘤新药诺维本联合化疗治疗晚期非小细胞肺癌 (NSCL C)的疗效及毒性反应 ,将晚期 NSCL C46例初治患者随机分为 2组 ,2 6例为 NP方案 :诺维本 (NVB) +顺铂 (DDP) ,2 0例为 NE方案 :诺维本 (NVB) +表阿霉素 (EPI)。 46例患者 CR 0例 ,PR 2 2例 ,总有效率 47.8%。白细胞减少发生率 :NP组 :78.8% ,NE组 :70 .0 % ;静脉炎发生率 :NP组 :48.0 % ,NE组 :42 .5 %。结果提示 :以诺维本为主的联合化疗治疗晚期非小细胞肺癌有效率高 ,毒性可以耐受 ,NP、 NE两组比较 ,有效率及毒性均无显著性差异 ,惟 NE组采用表阿霉素 ,治疗费用提高。
The efficacy and toxicity of combined navelbine (NVB) chemotherapy including NVB for the patients with advanced non small cell lung cancer (NSCLC) were studied. Forty six patients with advanced NSCLC were randomly divided into two groups: 26 patients received combined chemotherapy of NVB plus cisplatin (NVB+DDP, NP group) and the remaining 20 patients received combined chemotherapy of NVB plus epirubicin (NVB+EPI, NE group). It was found that no complete response was observed, partial response was observed in 22 patients with an overall response rate of 47.8 %. Neutropenia was seen in 78.8 % patients in NP group and 70.0 % in NE group, respectively. Phlebitis was seen in 48.0 % patients in NP group and 42.5 % in NE group, respectively. It was suggested that a high response rate was obtained in combined chemotherapy with NVB as a major agent for advanced NSCLC and the toxicity of NVB may endure. There was no significant difference in response rate and toxicity between NE group and NP group.
出处
《同济医科大学学报》
CSCD
2000年第4期327-328,共2页
Acta Universitatis Medicinae Tongji
